ETEbru Tarim

Ebru Tarim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ebru Tarim has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Can the 50-g glucose challenge test be important for subsequent pregnancies?

    by Ebru Tarim, Tayfun Cok, Cantekin Iskender

    Aim: Our aim in this study was to examine the risk factors associated with gestational diabetes mellitus (GDM) in women who did not have GDM during a previous pregnancy. Materials and methods: In this retrospective cohort study, we reviewed the charts of all pregnant women who delivered two pregnancies between January 2000 and June 2010. Group 1 consisted of patients with gestational diabetes and Group 2 served as the control. Results: There were 743 women who underwent GDM screening by means of the 50-g glucose challenge test (GCT). Thirty-eight women (5.1%) were excluded because of a previous history of GDM. The recurrence of GDM was 42.1% in this group (16 of the 38). The remaining 705 patients were divided into the GDM group (n = 38) and the control group (n = 667). Undergoing a 50-g GCT during the previous pregnancy (p = 0.000, 95% CI +0.01 to +0.002), age (p = 0.009, 95% CI +0.001 to +0.009), and weight differences between the pregnancies at the first trimester (p = 0.005, 95% CI +0.001 to +0.007) were independent parameters related to GDM. Conclusion: The 50-g GCT during the previous pregnancy was, interestingly, increased in the GDM group. It was also an independent risk factor for women without a history of GDM.


  • Isolated abnormal value during the 3-hour glucose tolerance test: which value is associated with macrosomia?

    by Tayfun Cok, Ebru Tarim, Tayfun Bagis

    Objective. The aim of this retrospective review was to evaluate obstetric outcomes in patients with an isolated abnormal value on the oral glucose tolerance test (OGTT) at 0, 1, 2, and 3 h. Methods. From January 2003 through June 2009, all consecutive pregnant women who presented to Baskent University were screened for gestational diabetes mellitus (GDM). Patients with one abnormal value based on findings of the OGTT were grouped according to increased levels of glucose at 0, 1, 2, and 3 h (Group 1 > 95 mg/dl for fasting glucose concentration, Group 2 > 180 mg/dl for the serum glucose concentration in the first hour, Group 3 > 155 mg/dl for the serum glucose concentration in the second hour, Group 4 > 140 mg/dl for serum glucose concentration in the third hour). The four groups were compared for classic GDM risk factors. The primary outcome measures were large for gestational age (LGA) (birthweight >95th percentile for gestational age using population birth weight centile charts) and macrosomia. Results. The incidence of LGA baby (Group 1, 10%; Group 2, 3.8%; Group 3 20.3%; Group 4, 13.2%; p = 0.008) was significantly highest in Group 3 and macrosomia (Group 1, 30%; Group 2, 5.1%; Group 3, 18.6%; Group 4, 15.8%; p = 0.039) was significantly higher in Groups 1 and 3. Conclusions. Our results suggest that even with relatively mild degrees of glucose intolerance at 2 h, no treatment is associated with LGA babies.


    • 1 January 2011
      • Vol. 38  (1) , 81-3

    Low molecular weight heparin and first trimester maternal PAPP-A and hCG levels, fetal nuchal translucency in the first trimester of pregnancy.

    by E Tarim, T Cok, S Hacivelioglu, T Bagis

    We studied the relation of first trimester nuchal translucency and first trimester biochemical markers using low molecular weight heparin (LMWH) at 11-14 weeks of gestation. This retrospective study was conducted at our university between January 2007 and July 2009. Ninety-six patients were treated with low-dose LMWHs (enoxaparine 40 mg) from the beginning of pregnancy to 36 weeks of gestation and low-dose aspirin (100 mg) to 32 weeks (group 1) and 100 control subjects (group 2) were included in the study. Transabdominal ultrasound examination was performed to diagnose any major fetal defects and for measurement of crown rump length (CRL) and fetal nuchal translucency (NT) thickness. Blood samples were drawn from each women PAPP-A and free beta hCG levels. There were no significant differences with respect to age, gestational age at the first trimester, and gestational age at birth between the groups. The mean birth weight of babies in the LMWH group was lower than the control (p = 0.026). There were also no significant differences with respect to CRL, serum PAPP-A and hCG at 11-14 weeks of gestation. However, NT of group 1 was significantly lower than group 2 (p = 0.000). In the Spearman correlation, LMWH was negatively correlated with only NT (r = -0.298, p = 0.000). NT in the first trimester (95% CI -0.632-0.230, p = 0.000) was an independent parameter related to using LMWH. Women who used LMWH during pregnancy had decreased NT compared with unaffected women.


  • First trimester maternal serum PAPP-A levels and macrosomia in nondiabetic mothers

    by Ebru Tarim, Servet Özden Haciveli̇oğlu, Tayfun Çok, Hali̇l Tayfun Bağiş

    To determine whether or not there is a relationship between first-trimester maternal serum pregnancy-associated placental protein (PAPP-A) levels and fetal macrosomia in nondiabetic mothers. Materials and methods: In this study, 63 consecutive term macrosomic neonates (Group 1) (birth weight >= 4000 g) and 100 consecutive appropriate-for-gestational-age (AGA) term neonates (Group 2) were included. Transabdominal ultrasound examinations were performed to diagnose any major fetal defects and to measure crown-rump length (CRL) and fetal nuchal translucency (NT) thickness. Blood samples were drawn from each woman in order to obtain fasting blood glucose, PAPP-A, and free beta-human chorionic gonadotropin (beta-hCG) levels. Ultrasound measurements of the fetal biparietal diameter, abdominal circumference, and femur length were obtained at 29-34 weeks of gestation. Results: The two groups were similar with respect to maternal age, parity, and gestational age in the first trimester. There were no significant differences between the groups in terms of the mean plasma levels of PAPP-A, free beta-HCG (as MoM values), mean CRL, and NT measurements. First-trimester PAPP-A levels were not correlated with birth weight (r = -0.116, P = 0.146), maternal age (r = 0.137, P = 0.089), maternal body mass index (BMI) in the first trimester (r = -0.037, P = 0.641) or at delivery (r = 0.042, P = 0.620), fasting blood glucose in the first trimester (r = -0.019, P = 0.816), macrosomia (r = -0.092, P = 0.249), or the occurrence of male sex (r = -0.074, P = 0.358) by the Pearson and Spearman correlations. In addition, first-trimester PAPP-A levels were not correlated with ultrasonographic measurements at 29-34 weeks of gestation. Conclusion: Although PAPP-A may promote fetal growth and development through metabolic and differentiation pathways, it seems that there is no relationship between PAPP-A levels and macrosomia.


  • Prenatal diagnosis and postmortem findings of Neu-laxova syndrome

    by Ebru Tarim, Filiz Bolat

    Neu-laxova syndrome is a lethal, autosomal recessive condition associated with ectodermal abnormalities and other characteristic features, including microcephaly, marked intrauterine growth restriction, limb deformities, central nervous system malformations and abnormal facial features, consisting of severe proptosis with ectropion, hypertelorism, micrognathia, flattened nose, malformed ears, and gaping mouth. Here we present a fetus having a dysmorphic face with proptotic eyes, retracted eye lids, depressed nasal bridge and micrognathia at 25 weeks of gestation. The extremities were contracted and no fetal movements were observed during the ultrasonographic examination. The fetus also had microcephaly and the amniotic fluid was increased. The pregnancy was terminated and the abnormalities demonstrated on prenatal ultrasound were confirmed at autopsy.


    • 1 December 2007
      • Vol. 98  (6) , 653-9

    Preventable thermal burns associated with the ignition of paint thinner: experience of a burn care network in Turkey.

    by M Haberal, A Kut, O Basaran, A Tarim, E Türk, E Sakallioglu, T Noyan, G Arslan

    This retrospective study evaluated the epidemiology of burn injuries, due to paint thinner ignition, in patients treated at the burn units of a university hospital network. From 1997 to 2005, 28 patients with thermal burns caused by ignition of paint thinner were admitted to our burn units. Age, sex, etiologic factors, extent and localization of burns, length of hospitalization, outcomes compared with other causes of thermal burns, and mortality rates were recorded for each patient. There were 25 males and 3 females. Mean age of the patients was 27.88+/-14.74 years. Two patients (7.4%) came from rural regions; the majority (92.9%; n=26) lived within city boundaries. The most common etiologic factor was attempting to start a fire in the stove with paint thinner. Mean extent of burns was 48.82+/-27.39% of the total body surface area. When compared with other flame burn causes, the extent of burns was significantly greater in paint-thinner burn patients. Affected body sites, in order of most affected to least affected, were the hands, feet, head and face, neck, and trunk and genital regions. Mean length of hospitalization for survivors was 39.65+/-37.83 days. The overall mortality rate was 39.3%. Sepsis (63.6%), excessive burns with inhalation injury (18.2%), pulmonary embolism (9.1%), and respiratory failure (9.1%) were the causes of the deaths. Paint thinner ignition may cause excessive burns with high mortality rates. Its common misuse in starting stove fires by persons living in urban areas should be prevented immediately.

  • Effects of aspirin on placenta and perinatal outcomes in patients with poor obstetric history

    by Ebru Tarim, Nebil Bal, Esra Kilicdag, Fazilet Kayaselcuk, Tayfun Bağış, Esra Kuscu

    Objective: The aim of this study was to compare a low-dose aspirin treatment on placental and perinatal effects in the patients with poor obstetric history such as preeclampsia, intrauterine growth retardation (IUGR) in previous pregnancy. Study design: This retrospective study of 86 pregnant women was conducted between April 2002 and June 2005. In this study period 364 placentas were examined and the patients with poor obstetric history such as IUGR and preeclampsia were selected. Then the patients were assigned to three groups; group 1 (n = 30) was composed of women with no risk in previous pregnancy; group 2 (n = 27) was composed of patients with poor obstetric history (e.g., preeclampsia, IUGR) who were treated with aspirin and patients in group 3 (n = 29) had poor obstetric history without any treatment (patients who were started to follow-up after 14 weeks of gestation). Patients in group 2 were treated with a low-dose aspirin (80 mg/day) as soon as a urinary pregnancy test was positive. Treatment was usually stopped at 34 completed weeks of gestation. On histopathologic examination of the placenta, uteroplacental vascular pathologic features and secondary villous damage (such as fibrinoid necrosis of desidual vessels, villous infarct, severely increased villous fibrosis, severely increased syncytiotrophoblast knotting, obliteration of the vessel lumen, severely increased villous hypervascularity) and also lesions involving coagulation (such as excessive perivillous fibrin deposition, multiple occlusive thrombi in uteroplacental vessels, avascular villi ) were examined. Results: There were no significant differences between the groups with respect to maternal age, body mass index at the first trimester and delivery. Also there were no significant differences among groups with respect to placental weight, fetal height, weight, gestational week, umbilical artery pH, pO2, pCO2 and base excess status. The incidences of preeclampsia were 3.3, 7.4, 6.8% and the incidences of IUGR were 6.7, 11.1, 6.8% in the groups, respectively (P > 0.05 for both). Although the percentages of all pathologic findings were higher in groups 2 and 3, these differences were not statistically important. Conclusion: When low-dose aspirin is taken, starting at the beginning of pregnancy in patients with poor obstetric history, there are still high frequencies of uteroplacental vascular and related villous lesions persisted on placental bed. Also it has no beneficial effects on perinatal outcomes in these patients.


  • Open Access

    Early onset of subclinical atherosclerosis in women with gestational diabetes mellitus

    by E. Tarim, F. Yigit, E. Kilicdag, T. Bagis, S. Demircan, E. Simsek, B. Haydardedeoglu, F. Yanik

    Objective Common carotid artery intima-media thickness (CIMT) is a non-invasively assessed marker of subclinical atherosclerosis. Our aim in this study was to investigate CIMT in women with gestational diabetes mellitus (GDM). Methods Thirty women with GDM and 40 unaffected women (as a control group) were included in the study. Blood samples were drawn from each woman in the morning after they had fasted for at least 8 h, and levels of fasting glucose, insulin, homocysteine, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein (VLDL) cholesterol were measured, along with the CIMT in the two groups. Results The mean triglyceride (P = 0.016) and VLDL cholesterol (P = 0.011) levels in the GDM group were significantly higher than those in the unaffected women. There were no significant differences between the groups with respect to plasma levels of total cholesterol, HDL cholesterol, LDL cholesterol and insulin. The mean homocysteine (P = 0.027) and fasting glucose (P = 0.019) levels in women with GDM were significantly higher than those in the control group. Patients with GDM had significantly higher CIMT than did the unaffected women (0.582 ± 0.066 mm vs. 0.543 ± 0.049 mm, P = 0.006). CIMT correlated positively with maternal age (r = 0.316, P = 0.008), body mass index (BMI) at the time of a 50-g oral glucose load test (r = 0.414, P = 0.001) and homocysteine levels (r = 0.332, P = 0.008), and fasting glucose (r = 0.265, P = 0.031) and 1-h glucose value (r = 0.410, P = 0.001) at the time of the oral glucose tolerance test. There was a positive correlation between the presence of GDM and CIMT (r = 0.372, P = 0.001). However, stepwise multiple regression analysis showed that GDM/no GDM (95% CI +0.012 to +0.076, P = 0.008) and BMI at the time of the 50-g test (95% CI +0.001 to +0.009, P = 0.011) were independent parameters related to CIMT. Conclusion Women with GDM have increased CIMT compared with unaffected women. Copyright © 2006 ISUOG. Published by John Wiley & Sons, Ltd.